Repurposing E3 ubiquitin ligases for targeted protein degradation via customized molecular
glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic …

Ubiquitination is a key post-translational modification of proteins, affecting the regulation of
multiple cellular processes. Cells are equipped with over 600 ubiquitin orchestrators, called …

Targeted protein degradation (TPD) has recently emerged as an exciting new drug modality.
However, the strategy of developing small molecule-based protein degraders has evolved …

Proteolysis targeting chimeras (PROTACs) are hetero-bifunctional small molecules
comprised of an E3 ligase recruiting molecule and the ligand for a protein of interest (POI) …

In recent years, proteolysis-targeting chimeras (PROTACs), capable of achieving targeted
protein degradation, have proven their great therapeutic potential and usefulness as …

Targeted protein degradation (TPD) using proteolysis targeting chimeras (PROTACs) and
molecular glue degraders has arisen as a powerful therapeutic modality for eliminating …

The discovery of new small molecule ligands for E3 ligases will enable the creation of novel
proteolysis targeting chimeras (PROTACs) and molecular glues to tackle traditionally …

Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are
a new modality of chemical tools and potential therapeutics to understand and treat human …

Small molecule heterobifunctional degraders (commonly also known as PROTACs) offer
tremendous potential to deliver new therapeutics in areas of unmet medical need. To deliver …

Methods to direct the degradation of protein targets with proximity-inducing molecules that
coopt the cellular degradation machinery are advancing in leaps and bounds, and diverse …